Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
暂无分享，去创建一个
E. Warren | R. Lynch | M. Shadman | R. Cassaday | A. Cowan | J. Fromm | C. Ujjani | E. Libby | M. Philip | A. Gopal | A. Shustov | B. Till | J. Voutsinas | Stephen D Smith | H. Coye | Christen N. Martino | Sandra L Bhark | K. Morris | Heather A. Rasmussen | S. Behnia | H. Rasmussen